TY - JOUR
T1 - Roadmap
T2 - Helium ion therapy
AU - Mairani, Andrea
AU - Mein, Stewart
AU - Blakely, Eleanor
AU - Debus, Jurgen
AU - Durante, Marco
AU - Ferrari, Alfredo
AU - Fuchs, Hermann
AU - Georg, Dietmar
AU - Grosshans, David R.
AU - Guan, Fada
AU - Haberer, Thomas
AU - Harrabi, Semi
AU - Horst, Felix
AU - Inaniwa, Taku
AU - Karger, Christian P.
AU - Mohan, Radhe
AU - Paganetti, Harald
AU - Parodi, Katia
AU - Sala, Paola
AU - Schuy, Christoph
AU - Tessonnier, Thomas
AU - Titt, Uwe
AU - Weber, Ulrich
N1 - Publisher Copyright:
© 2022 Institute of Physics Publishing. All rights reserved.
PY - 2022/8/7
Y1 - 2022/8/7
N2 - Helium ion beam therapy for the treatment of cancerwas one of several developed and studied particle treatments in the 1950s, leading to clinical trials beginning in 1975 at the Lawrence Berkeley National Laboratory. The trial shutdown was followed by decades of research and clinical silence on the topic while proton and carbon ion therapymade debuts at research facilities and academic hospitalsworldwide.The lack of progression in understanding the principle facets of helium ion beam therapy in terms of physics, biological and clinical findings persists today, mainly attributable to its highly limited availability.Despite this major setback, there is an increasing focus on evaluating and establishing clinical and research programs using heliumion beams, with both therapy and imaging initiatives to supplement the clinical palette of radiotherapy in the treatment of aggressive disease and sensitive clinical cases. Moreover, due its intermediate physical and radio-biological properties between proton and carbon ion beams, helium ions may provide a streamlined economic steppingstone towards an era of widespread use of different particle species in light and heavy ion therapy. With respect to the clinical proton beams, helium ions exhibit superior physical properties such as reduced lateral scattering and range stragglingwith higher relative biological effectiveness (RBE) and dose-weighted linear energy transfer (LETd) ranging from 4keVum?1 to 40 keVum?1. In the frame of heavy ion therapy using carbon, oxygen or neon ions,where LETd increases beyond 100 keVum?1, helium ions exhibit similar physical attributes such as a sharp lateral penumbra, however,with reduced radio-biological uncertainties and without potentially spoiling dose distributions due to excess fragmentation of heavier ion beams, particularly for higher penetration depths. This roadmap presents an overviewof the current state-of-The-Art and future directions of heliumion therapy: understanding physics and improvingmodeling, understanding biology and improving modeling, imaging techniques using helium ions and refining and establishing clinical approaches and aims from learned experiencewith protons.These topics are organized and presented into three main sections, outlining current and future tasks in establishing clinical and research programs using helium ion beams A. PhysicsB.Biological and C. Clinical Perspectives.
AB - Helium ion beam therapy for the treatment of cancerwas one of several developed and studied particle treatments in the 1950s, leading to clinical trials beginning in 1975 at the Lawrence Berkeley National Laboratory. The trial shutdown was followed by decades of research and clinical silence on the topic while proton and carbon ion therapymade debuts at research facilities and academic hospitalsworldwide.The lack of progression in understanding the principle facets of helium ion beam therapy in terms of physics, biological and clinical findings persists today, mainly attributable to its highly limited availability.Despite this major setback, there is an increasing focus on evaluating and establishing clinical and research programs using heliumion beams, with both therapy and imaging initiatives to supplement the clinical palette of radiotherapy in the treatment of aggressive disease and sensitive clinical cases. Moreover, due its intermediate physical and radio-biological properties between proton and carbon ion beams, helium ions may provide a streamlined economic steppingstone towards an era of widespread use of different particle species in light and heavy ion therapy. With respect to the clinical proton beams, helium ions exhibit superior physical properties such as reduced lateral scattering and range stragglingwith higher relative biological effectiveness (RBE) and dose-weighted linear energy transfer (LETd) ranging from 4keVum?1 to 40 keVum?1. In the frame of heavy ion therapy using carbon, oxygen or neon ions,where LETd increases beyond 100 keVum?1, helium ions exhibit similar physical attributes such as a sharp lateral penumbra, however,with reduced radio-biological uncertainties and without potentially spoiling dose distributions due to excess fragmentation of heavier ion beams, particularly for higher penetration depths. This roadmap presents an overviewof the current state-of-The-Art and future directions of heliumion therapy: understanding physics and improvingmodeling, understanding biology and improving modeling, imaging techniques using helium ions and refining and establishing clinical approaches and aims from learned experiencewith protons.These topics are organized and presented into three main sections, outlining current and future tasks in establishing clinical and research programs using helium ion beams A. PhysicsB.Biological and C. Clinical Perspectives.
KW - Dosimetry
KW - helium ion therapy
KW - Imaging
KW - Medical physics
KW - Radiation biology
UR - http://www.scopus.com/inward/record.url?scp=85133726979&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133726979&partnerID=8YFLogxK
U2 - 10.1088/1361-6560/ac65d3
DO - 10.1088/1361-6560/ac65d3
M3 - Article
C2 - 35395649
AN - SCOPUS:85133726979
SN - 0031-9155
VL - 67
JO - Physics in medicine and biology
JF - Physics in medicine and biology
IS - 15
M1 - 15TR02
ER -